Lind Global discloses 9.99% Enveric Biosciences (ENVB) ownership with warrants cap

Rhea-AI Filing Summary

Enveric Biosciences, Inc. received a Schedule 13G reporting a new significant passive holder. Lind Global Fund III LP, together with Lind Global Partners III LLC and Jeff Easton, reports beneficial ownership of 141,265 shares of common stock, equal to 9.99% of the class as of 01/28/2026.

The position consists of 79,366 common shares plus 79,366 Series G warrants and 79,366 Series H warrants, all subject to a 9.99% beneficial ownership limitation that caps how many warrant shares can be converted at any time. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Enveric.

Insights

Equity ownership & filings analyst

Lind Global and Jeff Easton report a capped 9.99% passive stake in Enveric Biosciences.

The filing shows Lind Global Fund III LP, its general partner Lind Global Partners III LLC, and managing member Jeff Easton jointly reporting 141,265 Enveric Biosciences common shares, representing 9.99% of the outstanding class as of 01/28/2026.

The stake includes 79,366 common shares plus Series G and Series H warrants for additional shares, all subject to a 9.99% beneficial ownership cap. This provision means warrant exercises cannot push their ownership above that threshold at any time, which limits immediate voting power and potential influence.

The reporting persons use a Schedule 13G and expressly certify the securities are not held to change or influence control of Enveric. This aligns the disclosure with a passive investment posture, though future filings would be required if their ownership or intent changes materially.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Enveric Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

29405E505

(CUSIP Number)

01/28/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 29405E505

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 141,265.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 141,265.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

141,265.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 79,366 shares of common stock, (ii) 79,366 warrants to purchase shares of common stock (the "Series G Warrants") and (iii) 79,366 warrants to purchase shares of common stock (the "Series H Warrants, together with the Series G Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 141,265 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.

SCHEDULE 13G

CUSIP No. 29405E505

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 141,265.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 141,265.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

141,265.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 79,366 shares of common stock, (ii) 79,366 Series G Warrants and (iii) 79,366 Series H Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 141,265 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.

SCHEDULE 13G

CUSIP No. 29405E505

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 141,265.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 141,265.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

141,265.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 79,366 shares of common stock, (ii) 79,366 Series G Warrants and (iii) 79,366 Series H Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 141,265 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Enveric Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 245 First Street, Riverview II, 18th Floor, Cambridge, Massachusetts, 02142
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund III LP, a Delaware limited partnership; o Lind Global Partners III LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.01 par value
(e)	CUSIP No.: 29405E505
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	02/04/2026

Lind Global Partners III LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	02/04/2026

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	02/04/2026

Exhibit Information

99.1 Joint Filing Agreement by and among the Reporting Persons.

FAQ

What stake in Enveric Biosciences (ENVB) does Lind Global report on this Schedule 13G?

Lind Global Fund III LP and related reporting persons disclose beneficial ownership of 141,265 Enveric Biosciences common shares, equal to 9.99% of the class as of January 28, 2026. This includes both common stock and warrant holdings subject to ownership limits.

How is Lind Global’s 9.99% Enveric (ENVB) position structured?

The reported 9.99% position consists of 79,366 common shares, plus 79,366 Series G warrants and 79,366 Series H warrants. Due to conversion limits in the warrants, Lind Global’s beneficial ownership is effectively capped at 141,265 shares at any given time.

What is the 9.99% beneficial ownership limitation in Enveric’s warrants held by Lind Global?

The Series G and Series H warrants include a 9.99% beneficial ownership limitation. This provision prevents the holder from converting warrants if doing so would cause beneficial ownership to exceed 9.99% of Enveric’s common stock, thereby capping voting and dispositive power from warrant exercises.

Who are the reporting persons on the Enveric Biosciences (ENVB) Schedule 13G?

The Schedule 13G is filed jointly by Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton. Lind Global Partners III LLC is the general partner of the fund, and Jeff Easton is its managing member, with deemed voting and dispositive power over the reported shares.

Is Lind Global’s 9.99% Enveric (ENVB) holding reported as a passive investment?

Yes. The reporting persons certify the securities "were not acquired and are not held" for the purpose of changing or influencing control of Enveric Biosciences. This language, and use of Schedule 13G, characterizes the stake as a passive ownership position under the disclosure rules.

What date triggers Lind Global’s Schedule 13G filing for Enveric Biosciences (ENVB)?

The Schedule 13G identifies January 28, 2026 as the Date of Event Which Requires Filing. This indicates that, as of that date, Lind Global and the other reporting persons crossed a disclosure threshold that required them to report their 9.99% beneficial ownership in Enveric.